Skip to main content

Comment on “usefulness of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?”

Dear Sir,

We read with great pleasure the important study evaluating the usefulness of atherogenic indices and carbamylated (Ca) low-density lipoprotein (LDL) (Ca-LDL) level to predict subclinical atherosclerosis in patients with psoriatic arthritis (PA)? by Tecer D et al. [1]. We have detected some important inaccuracies in their study’s results to especially in the atherogenic index of plasma (AIP) values.

The AIP is the logarithmic transformation of the triglyceride (TG)/high density lipoprotein (HDL) ratio. AIP has been reported to be a better marker than the TG/HDL ratio and other conventional indices in predicting cardiac disease risk. When calculating AIP, TG and HDL values should be taken in mmol/l [2]. AIP was defined as a low cardiac risk of < 0.11, intermediate cardiac risk of 0.11–0.21 and high cardiac risk of > 0.21 [2]. When calculating the AIP value, they received TG and HDL levels in mg/dl [1]. Because of this miscalculation, both the patient and the control group appear to be at high cardiac risk in their study [1]. In our estimation, the mean AIP value of their patient groups was 0.079 and the control group AIP value was 0.107 (both values are a low cardiac risk). The statistical results may change when both groups’ AIP value is calculated correctly.

According to current literature, AIP levels are not expected to be lower than the healthy control group in severe rheumatologic diseases [3]. Were both groups’ body mass index and waist circumference values matched? Were the comorbid conditions of the control group evaluated appropriately? The long-term effect of methotrexate (MTX) in reducing TG is known [4]. Most of their patients (76.9%) were taking MTX. Can MTX have affected the low AIP in the patient group than control?

TG level is a strong predictive marker for cardiovascular disease. There are many atherogenic LDL subtypes such as oxide-LDL, glycated-LDL, cLDL and sLDL; small dense LDL (sLDL) is responsible for the main atherogenic effect [5]. The TG value reflects the sLDL value [3]. Therefore, TG value is very important in determining atherogenic risk. cLDL leads to endothelial dysfunction and increased reactive oxygen radicals production. There is no information in the literature that cLDL is more atherogenic than sLDL until now. According to current literature, we think that sLDL is more atherogenic than cLDL. Also, we think that AIP is a better predictive marker than classical atherogenic indices and cLDL in determining cardiac risk.

Availability of data and materials

Not applicable.

References

  1. 1.

    Tecer D, Sunar I, Ozdemirel AE, Tural R, Kucuksahin O, Sepici Dincel A, et al. Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis? Adv Rheumatol. 2019;59(1):49.

    Article  Google Scholar 

  2. 2.

    Dobiasova M. Atherogenic index of plasma [log (triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113–5.

    CAS  Article  Google Scholar 

  3. 3.

    Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA, et al. Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS. Clin Rheumatol. 2018;37(5):1273–80.

    Article  Google Scholar 

  4. 4.

    Karimifar M, Sepehrifar MS, Moussavi H, Sepehrifar MB, Mottaghi P, Siavash M, et al. The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. J Res Med Sci. 2018;23:105.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Orekhov AN, Bobryshev YV, Sobenin IA, Melnichenko AA, Chistiakov DA. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Int J Mol Sci. 2014;15(7):12807–41.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

No funding was received.

Author information

Affiliations

Authors

Contributions

EC and MCC are the two authors of the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Erkan Cure.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cure, E., Cumhur Cure, M. Comment on “usefulness of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?”. Adv Rheumatol 60, 23 (2020). https://doi.org/10.1186/s42358-020-00128-6

Download citation